Werner Milton H. 4
4 · Inhibikase Therapeutics, Inc. · Filed Jan 7, 2025
Insider Transaction Report
Form 4
Werner Milton H.
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2025-01-03+5,315,056→ 5,315,056 totalExercise: $1.26Exp: 2035-01-03→ Common Stock (5,315,056 underlying) - Award
Stock Option (Right to Buy)
2025-01-03+2,207,671→ 2,207,671 totalExercise: $1.45Exp: 2035-01-03→ Common Stock (2,207,671 underlying) - Award
Stock Option (Right to Buy)
2025-01-03+4,059,744→ 4,059,744 totalExercise: $1.58Exp: 2035-01-03→ Common Stock (4,059,744 underlying)
Footnotes (3)
- [F1]The options vested and became exercisable on October 9, 2024.
- [F2]The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.
- [F3]The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.